/
Oncology
Solid Tumors
124
Pipeline Programs↗
95
Active Trials↗
121
Companies Involved↗
Solid Tumors is a highly competitive landscape with 124 programs across 121 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Revolution Medicines, Guangzhou Gloria Biosciences Co., Ltd.. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 156
Phase 250
Phase 38
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
91 of 115 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 115 classified programs, each share of the total. Modality classified for 100% of 124 pipeline programs.
Analysis
Trial Status
437
clinical trials
Completed211 · 48%
Terminated75 · 17%
Recruiting57 · 13%
Unknown status33 · 8%
Active, not recruiting24 · 5%
Withdrawn16 · 4%
Other21 · 5%
Clinical Trials
Trial Activity
437 trials
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06477614·60 enrolled
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
Recruiting·—·N/A·NCT06509490·9 enrolled
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT06195384·30 enrolled
Page 1 of 30
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)